OncoDaily Pulse

Aug 24, 2025, 11:32

Yu-Wei Chen: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register here: https://forms.gle/qcQyaGMQfHDhanfD9

Co-Chair of VIRO

Images Name

Rana McKay
Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Yu-Wei Chen

Dr. Yu-Wei Chen is an Assistant Professor of Medicine and Medical Oncologist at UC San Diego Health in San Diego, California. His clinical and research expertise focuses on advanced kidney cancers, with an emphasis on novel targeted therapies and integrating emerging agents into treatment pathways.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Chen will present on “Integration of HIF2α Inhibition in RCC: Later Line Treatment Approaches.” His session will explore the evolving role of HIF2α inhibitors in advanced renal cell carcinoma (RCC) and their place in treatment sequencing.

Dr. Chen will discuss

Current evidence supporting HIF2α inhibition in RCC.
Strategies for integrating HIF2α inhibitors in later-line treatment.
Clinical considerations in sequencing with immunotherapy and TKIs.
Future perspectives on expanding the use of HIF2α–targeted approaches.

Through his focus on targeted innovation, Dr. Chen will highlight how HIF2α inhibition is shaping the next frontier of advanced RCC management, bringing new hope for patients requiring later-line options.